Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$95.69

-0.67 (-0.70%)

, AGIO

Agios Pharmaceuticals

$73.42

-1.085 (-1.46%)

04:55
09/15/18
09/15
04:55
09/15/18
04:55

Society of Hematologic Oncology to hold annual meeting

SOHO 2018: 6th Annual Meeting will be held in Houston on September 12-15.

ABBV

AbbVie

$95.69

-0.67 (-0.70%)

AGIO

Agios Pharmaceuticals

$73.42

-1.085 (-1.46%)

ALXN

Alexion

$118.19

-0.84 (-0.71%)

AMGN

Amgen

$200.54

-2.4 (-1.18%)

AZN

AstraZeneca

$37.45

-0.17 (-0.45%)

BAYRY

Bayer

$0.00

(0.00%)

BMY

Bristol-Myers

$60.69

-0.11 (-0.18%)

CELG

Celgene

$87.18

-1.57 (-1.77%)

DNA

Bought by RHHBY

$0.00

(0.00%)

EPZM

Epizyme

$10.15

-0.05 (-0.49%)

GILD

Gilead

$73.38

-0.73 (-0.99%)

INCY

Incyte

$68.10

0.63 (0.93%)

JAZZ

Jazz Pharmaceuticals

$163.05

-2.17 (-1.31%)

KPTI

Karyopharm

$18.71

-0.15 (-0.80%)

LOXO

Loxo Oncology

$163.97

-1.38 (-0.83%)

MRK

Merck

$69.98

-0.4 (-0.57%)

NVS

Novartis

$85.26

-0.05 (-0.06%)

PFE

Pfizer

$42.97

0.11 (0.26%)

SGEN

Seattle Genetics

$78.22

1.02 (1.32%)

SHPG

Shire

$177.31

4.93 (2.86%)

SNSS

Sunesis

$1.86

-0.08 (-4.12%)

TEVA

Teva

$22.84

0.63 (2.84%)

  • 15

    Sep

  • 16

    Sep

  • 18

    Sep

  • 18

    Sep

  • 20

    Sep

  • 20

    Sep

  • 23

    Sep

  • 26

    Sep

  • 01

    Oct

  • 02

    Oct

  • 03

    Oct

  • 10

    Oct

  • 17

    Oct

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

  • 27

    Oct

  • 29

    Oct

  • 09

    Nov

  • 26

    Nov

  • 27

    Nov

  • 20

    Dec

  • 21

    Dec

  • 11

    Jan

  • 16

    Feb

  • 18

    Feb

ABBV AbbVie
$95.69

-0.67 (-0.70%)

09/10/18
BTIG
09/10/18
INITIATION
Target $32
BTIG
Buy
Voyager Therapeutics assumed with a Buy at BTIG
BTIG analyst Thomas Shrader assumed Voyager Therapeutics (VYGR) with a Buy rating and a price target of $32, saying the company is an "attractive investment" based on its lead product for late-stage Parkinson's Disease patients and its "robust" adeno-associated viral technology platform. The analyst expects Voyager to be well served in its upcoming gene therapy market share competition and also cites the company's "productive FDA meetings"and the start of of a phase 2 trial. Shrader further notes that Voyager Therapeutics' latest Abbvie (ABBV) deal is a "vote of confidence" for its program.
08/22/18
PIPR
08/22/18
NO CHANGE
Target $130
PIPR
Overweight
AbbVie decision suggests positive Argenx data, says Piper Jaffray
AbbVie's (ABBV) decision to exercise an exclusive option to license Argenx's (ARGX) anti-GARP antibody, ARGX-115, suggests positive preclinical data, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. The analyst looks for investigational new drug application filing plans this year. He reiterates an Overweight rating on shares of Argenx with a $130 price target.
08/08/18
HCWC
08/08/18
NO CHANGE
Target $44
HCWC
Buy
ObsEva price target raised to $44 from $30 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for ObsEva (OBSV) to $44 based on the disclosed pricing for AbbVie's (ABBV) Orilissa, the fgonadotropin-releasing hormone receptor antagonist for endometriosis and uterine fibroids. ObsEva management had previously guided to the cost of GnRH receptor antagonist therapy at $15 per day, about $450 per month, and the proposed monthly cost of Orilissa at $845 "appears to be comfortably above this level," Selvaraju tells investors in a research note. As such, the analyst elected to revise his pricing assumptions upward for ObsEva's linzagolix to reflect a daily cost of $25. He keeps a Buy rating on ObsEva shares.
08/29/18
HCWC
08/29/18
NO CHANGE
Target $44
HCWC
Buy
AbbVie study of elagolix reduces risk for ObsEva, says H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju believes AbbVie's (ABBV) long-term safety extension study of elagolix in women with uterine fibroids reduces risk for ObsEva (OBSV). The long-term efficacy for elagolix should bode well for future development of ObsEva's linzagolix in uterine fibroids, since both drugs are gonadotropin-releasing hormone receptor antagonists and have thus far shown comparable potency in clinical studies, Selvaraju tells investors in a research note. The analyst reiterates a Buy rating on ObsEva with a $44 price target.
AGIO Agios Pharmaceuticals
$73.42

-1.085 (-1.46%)

07/22/18
PIPR
07/22/18
NO CHANGE
Target $125
PIPR
Overweight
Agios' Tibsovo approved earlier, launch should go well, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren notes that Agios (AGIO) announced the FDA approval of Tibsovo for relapsed/refractory acute myeloid leukemia, which represents the company's second approved drug product within the past year. The analyst points out that both Tibsovo and Idhifa, which was approved August 2017, cover approximately 20% of all AML patients who harbor IDHm mutations. Due to partner Celgene (CELG) and Agios' existing Idhifa launch efforts and the strong awareness of and similarity between both products, Van Buren expects the Tibsovo launch to be as good as - if not better - than the early Idhifa launch. Over time, he believes that Tibsovo can treat the majority of U.S; AML patients with IDH1 mutations and generate sales approaching $150M. The analyst reiterates an Overweight rating and $125 price target on Agios shares.
08/02/18
PIPR
08/02/18
NO CHANGE
Target $125
PIPR
Overweight
Agios launch of Tibsovo should be as good as Idhifa, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren says he continues to believe that Agios Pharmaceuticals' (AGIO) launch of Tibsovo will be as good as, if not better, than the early Idhifa launch due to partner Celgene (CELG). Van Buren adds that while he "only" models $250M of U.S. sales in acute myeloid leukemia, the drug in this setting "could conceivably end up being several fold larger." Additionally, Agios management is being "appropriately vague" with the details of the dose-escalation in the ongoing Phase I study for AG-270, investors should be mindful of the fact that a response could be observed any day, which could be "very significant for the stock," Van Buren writes. The analyst keeps an Overweight rating on Agios Pharmaceuticals with a $125 price target.
06/04/18
PIPR
06/04/18
NO CHANGE
PIPR
Overweight
Agios' ivosidenib combo data support use in frontline AML, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren noted that the combo of ivosidenib plus Vidaza demonstrated "robust" clinical activity, including the rough doubling of ORR and CR rates compared to Vidaza monotherapy, and he believes the data shared at ASCO are supportive of the combination being used in the frontline AML setting. If these earlier trial results are replicated in the AGILE Phase 3 study, Van Buren sees a high probability of this combo being approved and used in the frontline AML setting, he tells investors. He maintains an Overweight rating on shares of Agios Pharmaceuticals, which are down 5% to $91.92 in afternoon trading.
09/06/18
ADAM
09/06/18
NO CHANGE
Target $90
ADAM
Buy
Agios ending AG-881 collaboration 'both positive and negative,' says Canaccord
While Celgene's (CELG) termination of the AG-881 collaboration may "suggest some lack of enthusiasm," it does give full rights back to Agios (AGIO), said Canaccord analyst John Newman, who believes "it is almost always better for a smaller biotech to have full commercial control of an asset." The analyst also noted that Jacqualyn Fouse is expected to assume the CEO role next February and Newman believes she will help maintain Agios' heading in launching approved products and developing the pipeline. Newman maintains a Buy rating and $90 price target on Agios shares.
ALXN Alexion
$118.19

-0.84 (-0.71%)

06/15/18
OPCO
06/15/18
NO CHANGE
OPCO
Outperform
Large-cap biotech fundamentals slowly improving, says Oppenheimer
Ahead of Q2 biotech earnings starting in mid-July, Oppenheimer analyst Hartaj Singh tells investors in a research note that large-cap fundamentals and sector sentiment are "slowly but surely" improving. Improving fundamentals indicate that large-cap biotech results could outperform in Q2, with Gilead (GILD), Alexion (ALXN) and Vertex (VRTX) leading the charge. Singh called out Vertex as "one of our favorite large-cap biotech names," and also says he believes the negative sentiment around Regeneron (REGN) "might be peaking." Singh, who has Outperform ratings on Alexion and Vertex and a Perform rating on Gilead and Regeneron, says he is "cautiously bullish" on the sector.
08/07/18
STFL
08/07/18
DOWNGRADE
Target $130
STFL
Hold
Alexion downgraded to Hold from Buy at Stifel
Stifel transferred coverage of Alexion to analyst Paul Matteis, who set a Hold rating and $130 price target on the shares, down from the firm's prior Buy rating. He has difficulty envisioning significant upside to mid-to-long-term consensus expectations given his worries about the risks associated with an increasingly challenging European payor environment and the breadth of drug development ongoing in the complement space, Matteis tells investors.
07/26/18
EVER
07/26/18
NO CHANGE
Target $158
EVER
Outperform
Alexion price target raised to $158 from $150 at Evercore ISI
Evercore ISI analyst Josh Schimmer said Alexion is "consistently conservative" on guidance and he wouldn't be surprised to see the company raise its outlook again in Q3 as it did with its Q2 report. He also noted that company reported "slight" delays for 1210 and its Wilson's program. Following the report, he raised his price target on Alexion to $158 and reiterated his Outperform rating on the shares.
07/26/18
PIPR
07/26/18
NO CHANGE
PIPR
Piper Jaffray would be buyers on Alexion weakness
Piper Jaffray analyst Christopher Raymond said in a research note that he believes the pressure in Alexion is "more macro-driven than company specific." He noted that with a solid Q2 beat and FY18 raise, along with continued pipeline progress and increased certainty with regard to the complement inhibition franchise's revenue tail, there is much to like with this name, and he would recommend buying the name on weakness. He kept an Overweight rating and $170 price target on Alexion shares.
AMGN Amgen
$200.54

-2.4 (-1.18%)

08/07/18
STFL
08/07/18
INITIATION
Target $30
STFL
Buy
Alder Biopharmaceuticals initiated with a Buy at Stifel
Stifel analyst Paul Matteis initiated coverage of Alder BioPharmaceuticals with a Buy rating and $30 price target, calling it an attractive, differentiated "pure play" within the migraine antiCGRP prevention market. While Matteis acknowledges it "won't be easy" for Alder to compete with Amgen (AMGN), Novartis (NVS), Eli Lilly (LLY) and Teva (TEVA), he believes the unique profile of eptinezumab remains underappreciated and may allow it to capture meaningful, above consensus share of a large, emerging drug category.
09/11/18
WELS
09/11/18
NO CHANGE
WELS
Amgen's AMG420 risk overstated, says Wells Fargo
Wells Fargo analyst Jim Birchenough believes shares of Bluebird Bio (BLUE) have been under pressure on concerns regarding potential competitive risk to BCMA CAR T therapeutic bb2121 from Amgen's (AMGN) bispecific T cell engager AMG420. The analyst highlights that AMGN420 is a continuous IV infusion and in his opinion not a viable competitor to a single bb2121 cell therapy dose, particularly given long-term durability of response with bb2121. Further, he notes that Amgen's approved first generation CD19 bispecific engager, BLINCYTO, is dosed as a continuous IV for 4 weeks out of every 6 and achieved only $175M in sales in 2017 following 2015 approval. He does not view this dose schedule for first generation bispecific T cell engagers as commercially viable in a more chronic cancer. Additionally, the analyst points out that Affimed (AFMD) also has a preclinical BCMA engager AFM26, established proof-of-concept data for CD30 bispecific AFM13, and upcoming proof-of-concept data for CD19 bispecific AFM11.
09/05/18
JEFF
09/05/18
NO CHANGE
Target $220
JEFF
Buy
Amgen shares should rally as biosimilar fears pass, says Jefferies
After meeting with Amgen's biosimilar head to discuss the current landscape, Jefferies analyst Michael Yee continues to believe Amgen shares should climb as the company manages numbers in the face of competition, especially as "fear" of initial competition and worst case scenarios pass. Amgen's Scott Foraker considers biosimilar competition as manageable against Neulasta, while also an attractive and profitable long-term business as Amgen has 10 of their own over next five years, Yee tells investors in a research note. The analyst keeps a Buy rating on Amgen with a $220 price target.
08/08/18
LEER
08/08/18
NO CHANGE
LEER
Regeneron, Amgen most exposed to Medicare Part B changes, says Leerink
After the Centers for Medicare and Medicaid Services announced that Medicare Advantage plans will have the option in 2019 of applying step therapy for physician-administered and other Part B drugs for new patients, Leerink analyst Geoffrey Porges said the end goal is to create MA plan formularies that can be used as a tool to negotiate with pharmaceutical makers for lower drug prices. Among the stocks he covers, Porges identifies Regeneron (REGN) and Amgen (AMGN) as among those with the most exposure to increased competitive intensity in Part B. For Regeneron, he sees the news re-igniting speculation about the threat of biosimilars and substitution with compounded Avastin, while for Amgen the change means that preference for its growth factor products facing biosimilar competition is likely to be challenged, the analyst said. Regeneron shares are down 4.6% to $373.34 in morning trading, while Amgen is down 2.2% to $195.89.
AZN AstraZeneca
$37.45

-0.17 (-0.45%)

09/14/18
ROTH
09/14/18
NO CHANGE
Target $33
ROTH
Buy
Roth Capital remains bullish on Stemline after AstraZeneca's Lumoxiti approved
Roth Capital analyst Jotin Marango said he had viewed the BLA review for AstraZeneca's (AZN) Lumoxiti for Hairy Cell Leukemia as a relative gauge of what might happen with Stemline's (STML) Elzonris given what he sees as the similarities between the agents. Lumoxiti's approval makes him more bullish on Stemline ahead of the Q1 of 2019 PDUFA date for Elzonris, said Marango, who raised his assumed probability of success for its BLA to 90% from 75%. He raised his price target on Stemline shares to $33 from $30 and keeps a Buy rating on the stock.
08/16/18
08/16/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AstraZeneca (AZN) downgraded to Hold from Buy at Jefferies with analyst Ian Hilliker citing valuation following the stock's outperformance since he upgraded it in March. 2. Cemex (CX) downgraded to Hold from Buy at HSBC with analyst Eduardo Altamirano saying Cemex's deleveraging remains intact, but the pace at which debt is converted to equity is slowing down due to weaker than expected pricing and volumes in most regions, combined with higher input costs. 3. Cenovus Energy (CVE) downgraded to Hold from Buy at Canaccord with analyst Dennis Fong saying cash flow valuation is in line versus the large-cap group, which he thinks is appropriate given the company's above-average heavy oil exposure, moderated production growth profile, and higher leverage. 4. Nanometrics (NANO) downgraded to Neutral from Buy at DA Davidson with analyst Thomas Diffely saying that after outperforming its peer group over the past few years, the stock now trades at a 40% premium to its peers. 5. Coty (COTY) downgraded to Underperform from Buy at BofA/Merrill with analyst Olivia Tong citing inconsistent execution and increasing disruption across the mass beauty segment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/05/18
PIPR
09/05/18
NO CHANGE
Target $48
PIPR
Overweight
Biohaven deal with AstraZeneca enhances leadership, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren says Biohaven Pharmaceutical (BHVN) has licensed a Phase III-ready central nervous system asset from AstraZeneca (AZN) that appears to have $500M-plus potential and "further broadens the company's pipeline." Based on his follow-up with management, the analyst believes the upfront cash payment is modest and that the Phase III trial will be efficient and require an estimated additional spend of $20M. Van Buren thinks the deal is an "attractively structured, efficient and opportunistic" that enhances Biohaven's leadership in CNS drug development. He keeps an Overweight rating on the shares with a $48 price target.
09/06/18
HCWC
09/06/18
NO CHANGE
Target $11
HCWC
Buy
H.C. Wainwright impressed by Checkpoint Therapeutics' first clinical data
H.C. Wainwright analyst Joseph Pantginis says Checkpoint Therapeutics' (CKPT) first clinical data in its history "did not disappoint." The data show a "significant clinical benefit" from CK-101 treatment, Pantginis tells investors in a research note. With these safety and efficacy data in hand, Checkpoint's CK-101 may show competitive clinical advantages versus approved EGFR therapies, including AstraZeneca's Tagrisso, at least in the non-small-cell lung carcinoma indication, the analyst contends. He's "impressed" with the data and notes that Checkpoint management has confirmed its intention to move into a pivotal study in 2019 mimicking the Tagrisso Flaura study. Pantginis has a Buy rating on Checkpoint Therapeutics with an $11 price target.
BAYRY Bayer
$0.00

(0.00%)

09/11/18
EXAN
09/11/18
DOWNGRADE
EXAN
Neutral
Bayer downgraded to Neutral from Outperform at Exane BNP Paribas
08/27/18
08/27/18
UPGRADE
Target $34

Neutral
Portola Pharmaceuticals upgraded to Neutral as MARINER sinks at Credit Suisse
As previously reported, Credit Suisse analyst Vamil Divan upgraded Portola Pharmaceuticals (PTLA) to Neutral from Underperform after Johnson & Johnson (JNJ)/Bayer (BAYRY) presented disappointing data for Xarelto in the acute medically ill population at ESC. The analyst notes that the data avoids a worst case scenario for Portola's Bevyxxa by essentially removing a potentially strong competitor, but does put the pressure on Portola to successfully change medical practice on its own, without help from a larger player such as Johnson & Johnson. Divan also raised his price target on Portola's shares to $34 from $28.
08/21/18
08/21/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Symantec (SYMC) upgraded to Positive from Neutral at Susquehanna with analyst Anne Meisner saying that activist shareholder Starboard Value disclosing a 5.8% stake and nominating five directors to its board has introduced the potential for positive change. 2. Johnson Controls (JCI) upgraded to Buy from Hold at Argus with analyst John Eade citing the company's recent Q3 earnings beat along with the technical breakout in its stock price above the $38 resistance. 3. Discovery (DISCA) upgraded to Buy from Hold at Jefferies with analyst John Janedis saying he sees "several" opportunities that could increase Discovery's free cash flow, including stronger U.S. distribution growth, upside to realized synergies and the potential for a re-introduction of a repurchase earlier than anticipated. 4. Estee Lauder (EL) upgraded to Buy from Neutral at DA Davidson with analyst Linda Bolton Weiser saying the company's fundamentals are the "strongest seen in years," with a 21% rise in FY18 operating profit and an "achievable and potentially beatable" EPS growth outlook of 9%-11% for FY19. 5. Bayer (BAYRY) upgraded to Buy from Hold at Berenberg. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/21/18
BREN
08/21/18
UPGRADE
BREN
Buy
Bayer upgraded to Buy from Hold at Berenberg
BMY Bristol-Myers
$60.69

-0.11 (-0.18%)

09/06/18
MSCO
09/06/18
NO CHANGE
Target $63
MSCO
Equal Weight
Bristol-Myers' TYK2 inhibitor may be underappreciated asset, says Morgan Stanley
Morgan Stanley analyst David Risinger said that Phase 2 data on Bristol-Myers' oral TYK2 inhibitor BMS-986165 will be presented at the EADV meeting on Wednesday September 12, adding that it could be an underappreciated asset if it offers better efficacy than other oral drugs and is safer. To his knowledge, no JAK inhibitors are currently being developed for psoriasis, Risinger noted. The analyst, who said 986165 "theoretically has blockbuster potential," maintains an Equal Weight rating on Bristol shares as further Opdivo lung newsflow is awaited.
09/12/18
FBCO
09/12/18
NO CHANGE
FBCO
Neutral
Bristol-Myers' TYK2 efficacy looks better than Otezla, says Credit Suisse
After Bristol-Myers (BMY) presented Phase 2 data for its oral TYK2 inhibitor, BMS-986165, in moderate-to-severe psoriasis at the EAVD meeting, Credit Suisse analyst Vamil Divan said he believes the "robust" data are very encouraging for the ongoing Phase 3 studies. BMS-986165 achieved PASI 75 response rates that are better than what was demonstrated by Celgene's (CELG) Otezla and the safety profile "appears reasonable," Divan tells investors. While BMS-986165 could be highly competitive clinically against other oral treatments, the crowded psoriasis market remains a tough one for new products, added the analyst, who keeps a Neutral rating on Bristol-Myers shares.
08/08/18
08/08/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Dean Foods (DF) upgraded to Hold from Sell at Deutsche Bank. 2. Plantronics (PLT) upgraded to Buy from Neutral at Sidoti with the firm citing attractive valuation. 3. CarGurus (CARG) upgraded to Outperform from Market Perform at JMP Securities and to Outperform from Sector Perform at RBC Capital. 4. Bristol-Myers (BMY) upgraded to Neutral from Underweight at Atlantic Equities. 5. Floor & Decor (FND) upgraded to Buy from Hold at Loop Capital with analyst Anthony Chukumba saying the company continues to post the "best relative performance in the flooring retailing industry." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/08/18
ATLE
08/08/18
UPGRADE
ATLE
Neutral
Bristol-Myers upgraded to Neutral from Underweight at Atlantic Equities
CELG Celgene
$87.18

-1.57 (-1.77%)

08/08/18
RBCM
08/08/18
NO CHANGE
Target $110
RBCM
Outperform
RBC Capital revisits idea of Celgene going private after Tesla proposal
Following yesterday's news that Tesla (TSLA) CEO Elon Musk would like to see his company go private, RBC analyst Brian Abrahams revisited his prior analysis of whether Celgene (CELG) should go private in order to better capture the medium-term value of future Revlimid cash flows not being appreciated by public markets and avoid volatility as it transitions to a post-Revlimid business model. Though acknowledging that the two companies are in completely different industries, he thinks the example of Musk shows that performing such a transaction on a large company "may not be completely unrealistic," Abrahams said. Such an LBO, or perhaps more likely an acquisition by a larger pharmaceutical company, could possibly help capture more value from Celgene's commercial and pipeline products, concludes Abrahams, who has an Outperform rating and $110 price target on Celgene shares.
07/30/18
RHCO
07/30/18
NO CHANGE
Target $101
RHCO
Hold
Celgene price target raised to $101 from $96 at SunTrust
SunTrust analyst Yatin Suneja raised his price target on Celgene to $101 after its Q2 results, saying the company saw "good performances from all core products except Otezla and Abraxan", while its updated FY18 outlook also reflects its larger than anticipated share buyback. Suneja further notes that Celgene's pipeline assets ozanimod, fedratinib, luspatercept and the CAR-T programs are all progressing towards filings, which may help the company diversify its pipeline away from Revlimid. The analyst also keeps his Hold rating, noting that any near-term contribution from its extensive pipeline are likely to be limited.
DNA Bought by RHHBY
$0.00

(0.00%)

10/13/17
KEYB
10/13/17
NO CHANGE
Target $106
KEYB
Overweight
Auto suppliers supported by stronger Euro and rising EU output, says KeyBanc
KeyBanc analyst Brett Hoselton raised his profit targets on several auto suppliers, maintaining a positive view on the group overall heading into Q3 earnings. Hoselton says the outlook for the quarter is intact, as lower than expected production of light vehicles was in part offset by stronger EU output. He also cites FX tailwinds, with the Euro have appreciated about 7% sequentially and further supporting revenue in Q3 and possibly FY18. Hoselton raised his profit targets on Delphi Automotive (DLPH) to $106 from $100, Magna International (MGA) to $59 from $55, Lear Corp (LEA) to $184 from $180, and BorgWarner (BWA) to $56 from $50, maintaining an Overweight rating on all these stocks. The analyst is especially bullish on Dana Inc (DNA) given the recent upward revisions to North America Class 8 production, but says his Sector Weight rating reflects the stock prices.
EPZM Epizyme
$10.15

-0.05 (-0.49%)

08/03/18
JEFF
08/03/18
NO CHANGE
Target $22
JEFF
Buy
Epizyme looks oversold after yesterday's pullback, says Jefferies
Jefferies analyst Michael Yee attributes the selloff yesterday in shares of Epizyme to the delay and push-out of the new drug application to the first half of 2019 and uncertainty around the partial clinical hold. The stock is becoming more of a "2019 play" for the NDA filing and full EZH2 data, Yee tells investors in a research note. Over the short term, the analyst views the stock as oversold and thinks it will bounce back on removing the clinical hold over the next two months. Yee keeps a Buy rating on Epizyme and lowered his price target for the shares to $22 from $27.
05/18/18
WEDB
05/18/18
NO CHANGE
Target $25
WEDB
Outperform
Epizyme price target raised to $25 from $20 at Wedbush
Wedbush analyst David Nierengarten raised his price target on Epizyme to $25 from $20, telling investors in a research note that abstracts from The European Hematology Association show responses are deepening in the EZH2-wt follicular lymphoma cohort, increasing his confidence that tazemetostat will find a broad use in FL regardless of mutation status. However, the analyst noted that he is "less certain" on the future for the drug in mesothelioma, where low response rates seen in a Phase 2 trial indicate a more challenging path forward.
07/03/18
LEER
07/03/18
DOWNGRADE
LEER
Market Perform
Epizyme downgraded to Market Perform from Outperform at Leerink
09/07/18
MSCO
09/07/18
INITIATION
Target $12
MSCO
Equal Weight
Epizyme resumed with an Equal Weight at Morgan Stanley
Morgan Stanley analyst David Lebowitz resumed coverage of Epizyme with an Equal Weight rating and $12 price target, recommending investors stay on the sidelines despite tazemetostat's potential as the partial clinical hold imposed in April by the FDA clouds the timing and increases the level of risk for the drug.
GILD Gilead
$73.38

-0.73 (-0.99%)

09/13/18
JPMS
09/13/18
INITIATION
Target $140
JPMS
Overweight
Galapagos NV initiated with an Overweight at JPMorgan
JPMorgan analyst James Quigley started Galapagos NV (GLPG) with an Overweight rating and $140 price target. The company's key value driver is filgotinib, a selective JAK1 inhibitor which has shown potential best in class data in inflammatory diseases and is licensed to Gilead (GILD), Quigley tells investors in a research note. The analyst forecasts peak in market filgotinib sales of EUR 4.4B. Quigley also sees value in Galapagos' wholly owned GLPG1690, which he says could be the first drug to halt disease progression in idiopathic pulmonary fibrosis.
09/12/18
NOMU
09/12/18
NO CHANGE
Target $124
NOMU
Buy
Galapagos data meets expectations 'and then some,' says Nomura Instinet
Nomura Instinet analyst Christopher Marai says Galapagos NV (GLPG) and Gilead's (GILD) positive top-line results from the Finch-2 study evaluating filgotinib in moderate-to-severe rheumatoid arthritis patients met his expectations "and then some." The anlayst keeps a Buy rating on Galapagos with a $124 price target.
08/22/18
JEFF
08/22/18
NO CHANGE
Target $4.29
JEFF
Buy
Sierra Oncology acquisition brings late-stage asset, says Jefferies
Jefferies analyst Maury Raycroft says that while Sierra Oncology's acquisition of momelotinib came as a surprise at first, about half of the company's management has experience with the drug stemming back to Cytopia. The move is opportunistic and provides an active drug that was too small for Gilead (GILD) and "potentially just right" for Sierra, Raycroft tells investors in a research note. The late-stage drug comes with valuable historical dataset that Sierra can potentially leverage and the deal terms are favorable, the analyst contends. He keeps a Buy rating on Sierra Oncology with a $4.29 price target.
09/12/18
PIPR
09/12/18
NO CHANGE
Target $85
PIPR
Overweight
Gilead's filgotinib data look in-line with expectations, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren says Gilead's topline Phase III filgotinib data in biologic-inadequate patients appear in-line with expectations. The analyst believes the Phase III Finch 1 in MTX-inadequate responders and Finch 3 in MTX-naive patients readouts in the first half of 2019 are now "highly likely" o be successful. Further, it appears that filgotinib will have a competitive clinical profile as response and remission rates were in-line or towards the top end of the range when compared to the class at the 12 week endpoint and safety was clean, Van Buren tells investors in a research note. However, the analyst does not believe that the data were enough to clearly separate filgotinib from the competing agents in the class. As such, believes his current sales estimates which approach $1.5B by the mid-2020s are reasonable. The analyst keeps an Overweight rating on Gilead with an $85 price target.
INCY Incyte
$68.10

0.63 (0.93%)

09/13/18
JANY
09/13/18
INITIATION
Target $17
JANY
Neutral
Janney Montgomery Scott starts Concert Pharmaceuticals at Neutral
As previously reported, Janney Montgomery Scott initiated Concert Pharmaceuticals (CNCE) with a Neutral rating, with analyst Esther Hong setting a $17 fair value estimate on the shares. She believes AVP-786, which is in Phase 3 in Alzheimer's agitation, has blockbuster potential and she is positive on its lead program, CTP-543 for the treatment of Alopecia Areata. However, Hong remains on the sidelines pending the final decision on CTP-543's patent after Incyte filed an Inter Partes Review petition, noting that the PTAB granted a rehearing request, which it rarely does. She sees the IPR ruling as difficult to predict at this stage.
08/15/18
08/15/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nvidia (NVDA) double-upgraded two notches to Outperform from Underperform at Wells Fargo with analyst Aaron Rakers citing the company's long-term prospects given its competitive position in gaming as well as its AI / deep learning data center growth opportunities. 2. Hasbro (HAS) upgraded to Buy from Neutral at MKM Partners with analyst Eric Handler saying investors should look beyond the 2018 industry issues and anticipate a "material fundamental recovery" in the next two years thanks to the company's large toy line additions and expected margin expansion. 3. Incyte (INCY) upgraded to Outperform from Sector Perform at RBC Capital with analyst Brian Abrahams citing the company's "unique situation" position as a "revenue-generating, high-opex, broad-pipeline mid-cap, which should enable it to pull multiple levers" to unlock value and produce shareholder interest. 4. Norfolk Southern (NSC) upgraded to Buy from Hold at Deutsche Bank reflecting increased conviction that out-year earnings power is underappreciated. 5. Papa John's (PZZA) upgraded to Hold from Sell at Stifel with analyst Chris O'Cull saying he believes near-term expectations have been reset to a reasonable level following the company's disappointing Q2 results and report of "lackluster" same-store sales in Q3 to-date. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/10/18
RBCM
09/10/18
NO CHANGE
RBCM
Outperform
Incyte offering a 'buying opportunity on weakness' says RBC Capital
RBC Capital analyst Brian Abrahams kept his Outperform rating on Incyte, saying that Friday's selloff on the announced departure of its CFO is a "buying opportunity" as the stock remains a "compelling value". The analyst notes that the recent rise in the stock price reflects the recognition of its "solid commercial and broad pipeline assets", further pointing out the potential for the company to improve efficiencies in its business model.
08/30/18
ARGS
08/30/18
NO CHANGE
Target $83
ARGS
Buy
Incyte pullback is a 'buying opportunity', says Argus
Argus analyst Jasper Hellweg kept his Buy rating and $83 price target on Incyte, saying the recent weakness in its stock price offers a "buying opportunity". The analyst expects continued strength to come from the company's Iclusig and Jakafi "key products", along with a new growth opportunity from the U.S. launch of Olumiant and the possibility of an FDA approval of Jakafi as a treatment for graft-versus-host-disease. Hellweg also believes that Incyte may be an acquisition target, stating that its valuation is "attractive" at the current $72 per share price given its 52-week trading range of $60-$140.
JAZZ Jazz Pharmaceuticals
$163.05

-2.17 (-1.31%)

08/06/18
MSCO
08/06/18
NO CHANGE
MSCO
Boeing, Tesla, Nvidia make Morgan Stanley 'key man risk' list
Morgan Stanley equity strategist Mark Savino noted that about 12% of CEO jobs among S&P 500 companies turned over in 2017, noting that this was the highest level of CEO departures since before the financial crisis. The 59 stocks of S&P 500 companies that had CEOs depart in 2017 underperformed the market by 11% over the next 12 months, or since the departure for instances that were less than 12 months ago, noted Savino. In cooperation with the firm's U.S. analysts, Savino and his team identified the companies in each sector they believe face the greatest level of "key man risk," which includes: Boeing (BA), Tesla (TSLA), ADT Inc. (ADT), Moody's (MCO), TransUnion (TRU), Arista Networks (ANET), Church & Dwight (CHD), Coca-Cola (KO), Monster Beverage (MNST), Coupa Software (COUP), Salesforce (CRM), FireEye (FEYE), MongoDB (MDB), Microsoft (MSFT), New Relic (NEWR), XPO Logistics (XPO), Hilton (HLT), Las Vegas Sands (LVS), Best Buy (BBY), Ulta (ULTA), Aflac (AFL), Athene Holding (ATH), Lincoln National (LNC), Arthur J. Gallagher (AJG), Chubb (CB), Amazon.com (AMZN), Activision Blizzard (ATVI), Facebook (FB), Alphabet (GOOGL), Apple (AAPL), Terex (TEX), Cleveland-Cliffs (CLF), Freeport McMoRan (FCX), FleetCor (FLT), Global Payments (GPN), Square (SQ), Jazz Pharmaceuticals (JAZZ), Cheesecake Factory (CAKE), Broadcom (AVGO), Nvidia (NVDA), Chegg (CHGG), DXC Technology (DXC), Medidata (MDSO), Pluralsight (PS), RealPage (RP), Shopify (SHOP) and T-Mobile (TMUS).
08/17/18
LEER
08/17/18
NO CHANGE
Target $210
LEER
Outperform
Jazz Pharmaceuticals price target raised to $210 from $200 at Leerink
Leerink analyst Ami Fadia raised Jazz Pharmaceuticals for solriamfetol based on results from the firm's MEDACorp physician survey on the Excessive Sleepiness market. Fadia continues to see solriamfetol as a key growth asset in the outer years when Xyrem faces competition. The analyst rates Jazz an Outperform and increased its price target to $210 from $200.
08/15/18
WELS
08/15/18
NO CHANGE
Target $195
WELS
Outperform
Jazz Pharmaceuticals price target raised to $195 from $182 at Wells Fargo
Wells Fargo analyst David Maris raised his price target for Jazz Pharmaceuticals to $195 from $182 as he believes it continues to execute well on the commercial side and on its pipeline-driven strategy. The analyst likes the conservative balance sheet, the current sales trends, and the focus on pipeline progress. He reiterates an Outperform rating on the shares.
07/16/18
CANT
07/16/18
NO CHANGE
Target $203
CANT
Overweight
Cantor sees 'meaningful upside' in shares of Jazz Pharmaceuticals
Cantor Fitzgerald analyst William Tanner sees "meaningful upside" in shares of Jazz Pharmaceuticals from current levels. The analyst views recent legal developments as positive, "on balance," and thinks any announcement on the business development front "could be a major incremental driver of positive sentiment." He reiterates an Overweight rating on Jazz with a $203 price target.
KPTI Karyopharm
$18.71

-0.15 (-0.80%)

05/24/18
WEDB
05/24/18
DOWNGRADE
WEDB
Neutral
Karyopharm downgraded to Neutral from Outperform at Wedbush
05/24/18
05/24/18
DOWNGRADE
Target $19

Neutral
Karyopharm downgraded to Neutral at Wedbush
As previously reported, Wedbush analyst David Nierengarten downgraded Karyopharm to Neutral from Outperform on valuation. The analyst also lowered his price target on the shares to $19 from $20 as he updates his model for the company's offering and for a somewhat shorter duration of therapy based on the STORM duration of response of 4.4 months.
05/24/18
HCWC
05/24/18
NO CHANGE
Target $30
HCWC
Buy
H.C. Wainwright remains bullish Karyopharm after STORM data, license deal
H.C. Wainwright analyst Edward White reiterates a Buy rating and $30 price target for Karyopharm, while pointing out that recent positive Phase 2b STORM data confirmed his expectations for the success of selinexor. The company expects a NDA submission for an accelerated approval of selinexor in patients with penta-refractory multiple myeloma in 2H18, he says, adding that he estimates the addressable peak market size for this population is over $500M in the U.S. The analyst also notes that the company has announced an exclusive license agreement for the development and commercialization of selinexor, eltanexor, verdinexor and KPT-9274 with Antengene Corporation.
05/24/18
05/24/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AbbVie (ABBV) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Jami Rubin citing share outperformance. 2. Petrobras (PBR) downgraded to Equal Weight from Overweight at Morgan Stanley, to Neutral from Outperform at Credit Suisse, to Neutral from Buy at BofA/Merrill, and to Market Perform from Outperform at Itau BBA. 3. Karyopharm (KPTI) downgraded to Neutral from Outperform at Wedbush with analyst David Nierengarten citing valuation. 4. Vermillion (VRML) downgraded to Hold from Buy at Canaccord. 5. Generac (GNRC) downgraded to Neutral from Outperform at Baird. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
LOXO Loxo Oncology
$163.97

-1.38 (-0.83%)

07/12/18
OPCO
07/12/18
NO CHANGE
Target $202
OPCO
Outperform
Loxo Oncology price target raised to $202 from $122 at Oppenheimer
Oppenheimer analyst Leah Rush Cann raised her price target for Loxo Oncology to $202 from $122 to account for an increased average forward price-to-sales multiple of the biotechnology sector. The analyst reiterates an Outperform rating on the shares.
08/13/18
SBSH
08/13/18
NO CHANGE
Target $235
SBSH
Buy
Citi opens 90-day positive catalyst watch for Loxo Oncology
Citi analyst Yigal Nochomovitz opened a 90-day positive catalyst watch for Loxo Oncology in anticipation of updated duration of therapy data for lead asset larotrectinib at the European Society for Medical Oncology meeting in October. The analyst is expecting positive data, meaning increased average duration of at least six months, and sees the stock up 15%-20% on the news. He has a Buy rating on Loxo shares with a $235 price target.
07/05/18
RHCO
07/05/18
INITIATION
Target $60
RHCO
Buy
Deciphera initiated with a Buy at SunTrust
SunTrust analyst Peter Lawson initiated Deciphera (DCPH) with a Buy rating and a price target of $60, citing the company's differentiated position of developing kinase inhibitors that can hit multiple mutations, potentially better controlling cancer. Given its wholly owned pipeline of 3 clinical drugs, the lead of which is targeting Gastrointestinal stromal tumor in two phase 3 trials by the second half of this year, the analyst recommends that investors acquire shares ahead of those readouts. Lawson further states that other kinase targeting peer companies such as Loxo Oncology (LOXO), Blueprint Medicines (BPMC), and Mirati Therapeutics (MRTX) also point to significant upside amid clinical validation progress.
06/05/18
06/05/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Ulta Beauty (ULTA) downgraded to Neutral from Buy at Goldman Sachs with analyst Matthew Fassler saying shares have recently recovered, but sales momentum continues to moderate following a deceleration for six consecutive quarters in same-store-sales. 2. Take-Two (TTWO) downgraded to Market Perform from Outperform at BMO Capital with analyst Gerrick Johnson saying he is "concerned" expectations for the Red Dead Redemption 2 release could be overly optimistic and sees a risk to earnings from a potential slowdown in Grand Theft Auto and NBA 2K. 3. Loxo Oncology (LOXO) downgraded to Market Perform from Strong Buy at IFS Securities. 4. Dentsply Sirona (XRAY) downgraded to Neutral from Buy at Northcoast. 5. First Solar (FSLR) downgraded to Neutral from Buy at BofA/Merrill with analyst Julien Dumoulin-Smith saying she expects a "steep" drop in 2018 Chinese solar deployments following China's recent 2018 Solar PV Power Generation Notice, with further declines in 2019/2020 possible. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MRK Merck
$69.98

-0.4 (-0.57%)

06/14/18
MSCO
06/14/18
NO CHANGE
Target $68
MSCO
Overweight
Merck Q2 estimates lowered below consensus at Morgan Stanley
Morgan Stanley analyst David Risinger cut his Q2 revenue estimate for Merck by 1% to $10.1B, which he notes is below the consensus view of $10.3B, and lowered his Q2 EPS estimate by 6% to 97c. This is below the consensus view of $1.03, which he argues "needs to come down." The two key drivers were lowering his estimates for Keytruda in the U.S. due to a more gradual ramp in first-line lung cancer patients and the negative impact of hedging, which he sees being similar to, but less pronounced, than in Q1. He lowered his full-year EPS view by only 1%, however, which puts it 2% below consensus. Risinger keeps an Overweight rating and $68 price target on Merck shares.
06/28/18
WELS
06/28/18
NO CHANGE
WELS
Wells says Amazon deal, Walgreens results have negative read for drug pricing
After Amazon (AMZN) agreed to acquire online pharmacy PillPack, reportedly for $1B, Wells Fargo analyst David Maris noted that he has long stated that Amazon would enter the pharmacy business and warned about the risk to drug pricing in such a scenario. Maris also noted that Walgreens (WBA) reported its U.S. retail pharmacy comparable store sales fell 1.2% in Q3, adding that retailers tend to push drugmakers on price when they feel pressure and the read-through from its report may be negative for drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
08/23/18
MSCO
08/23/18
NO CHANGE
Target $74
MSCO
Overweight
Merck price target raised to $74 from $68 at Morgan Stanley
Morgan Stanley analyst David Risinger maintained an Overweight rating on Merck and raised his price target to $74 from $68, citing his expectation for operating leverage to become more visible in 2019 and pipeline progress to improve perception about prospects in the face of Januvia generics in January 2023. Looking ahead, Risinger projects Merck's 5-year CAGR from 2018-2023 for revenue growth of 3% and EPS growth of 8%. Risinger says he believes the primary driver of major pharma stock performance in recent months is "defensive rotation." Looking ahead, the analyst says to watch for U.S. pricing perception drivers in the coming months that could impact pharma stock performance, including potential additional HHS action on drug rebates, November election results and manufacturer communication and action on U.S. list prices by early January.
NVS Novartis
$85.26

-0.05 (-0.06%)

09/11/18
09/11/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nike (NKE) upgraded to Buy from Hold at Canaccord with analyst Camilo Lyon saying he believes Nike has regained its footing and is marching back to form following two years of a soft product cycle, margin compression, and market share declines. 2. Novartis (NVS) upgraded to Buy from Neutral at Citi and to Neutral from Underperform at Exane BNP Paribas. 3. Darden (DRI) upgraded to Buy from Neutral at Goldman Sachs while Bloomin' Brands (BLMN) was upgraded to Neutral from Sell. 4. South Jersey Industries (SJI) upgraded to Overweight from Neutral at JPMorgan with analyst Christopher Turnure saying the company's "superior" growth potential is coming into focus while its shares trade at a discount to peers. 5. Snap (SNAP) upgraded to Outperform from Neutral at Wedbush with analyst Michael Pachter noting that decelerating growth trends, fierce competition for user mindshare and advertiser dollars, and a history of being hugely unprofitable have kept him on the sidelines, but recent management changes and improved execution have led him to update his outlook. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/11/18
SBSH
09/11/18
UPGRADE
SBSH
Buy
Novartis upgraded to Buy from Neutral at Citi
Citi upgraded Novartis to Buy from Neutral. Exane BNP Paribas also upgraded the shares this morning to Neutral.
09/11/18
EXAN
09/11/18
UPGRADE
EXAN
Neutral
Novartis upgraded to Neutral from Underperform at Exane BNP Paribas
09/11/18
EXAN
09/11/18
UPGRADE
EXAN
Neutral
Novartis upgraded to Neutral from Underperform at Exane BNP Paribas
Exane BNP Paribas analyst Kerry Holford upgraded Novartis to Neutral and a price target of CHF 79. Performance of the company's key growth assets has improved, Holford tells investors in a research note. This improved performance will help offset the sales and profit erosion from upcoming patent expirations on Glivec, Afinitor, Exjade, Gilenya, the analyst contends.
PFE Pfizer
$42.97

0.11 (0.26%)

09/11/18
BARD
09/11/18
NO CHANGE
Target $85
BARD
Outperform
Exact Sciences price target raised to $85 from $74 at Baird
Baird analyst Catherine Ramsey Schulte raised her price target on Exact Sciences (EXAS) to $85 from $74 citing increased confidence in its partnership with Pfizer (PFE). She sees several different potential outcomes given different assumptions for Pfizer rep productivity and order rate increases. Schulte reiterated her Outperform rating on Exact Sciences shares.
09/12/18
ADAM
09/12/18
NO CHANGE
Target $87
ADAM
Buy
Exact Sciences price target raised to $87 from $72 at Canaccord
Canaccord analyst Mark Massaro raised his price target on Exact Sciences (EXAS) as he updated his model to include the contribution of Pfizer (PFE) reps. Massaro, who believes the company is well positioned to expand its business and he raised his estimates, reiterated his Buy rating on Exact Sciences shares.
09/06/18
BMOC
09/06/18
NO CHANGE
Target $47
BMOC
Outperform
Pfizer price target raised to $47 from $44 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Pfizer to $47 and kept his Outperform rating, citing the company's Tafamidis potential prospects of $3.5B or more in sales by 2027. The analyst notes that Transthyretin Amyloid Cardiomyopathy, or ATTR-CM, is a "fatal, under-diagnosed heart disease with no approved treatments", but the new method of diagnosis could ramp up from 1% to 20%, supporting the "robust efficacy" with "benign safety" offered by the company's treatment. Arfaei further contends that Pfizer's 3.5% dividend yield and 14-times forward earnings multiple make the stock attractive.
09/06/18
BOFA
09/06/18
NO CHANGE
Target $92
BOFA
Buy
Exact Sciences price target raised to $92 post Pfizer deal at BofA/Merrill
BofA/Merrill analyst Derik de Bruin said Exact Sciences (EXAS) co-promotion agreement for Cologuard with Pfizer (PFE) adds significant "marketing muscle" to the company's strong fundamental story. The deal will help Exact Sciences penetrate healthcare systmes and allow the company to increase its advertising and promotional spect through better rates by utilizing Pfizer's purchasing power, the analyst wrote in a note to investors. de Bruin reiterates his Buy rating on Exact Sciences and increased his price target to $92 from $68 on shares.
SGEN Seattle Genetics
$78.22

1.02 (1.32%)

06/11/18
RHCO
06/11/18
UPGRADE
RHCO
Buy
Seattle Genetics upgraded to Buy from Hold at SunTrust
09/06/18
PIPR
09/06/18
INITIATION
Target $71
PIPR
Neutral
Seattle Genetics assumed with a Neutral at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro assumed coverage of Seattle Genetics with a Neutral rating but raised the firm's price target on the shares to $71 from a prior target of $55. He sees Adcetris being poised for blockbuster status, but is not as convinced about the long-term adoption in first-line Hodgins Lymphoma as consensus estimates indicate.
07/27/18
HCWC
07/27/18
NO CHANGE
Target $98
HCWC
Buy
Seattle Genetics price target raised to $98 from $77 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised his price target for Seattle Genetics to $98 citing "progress on multiple fronts." The analyst reiterates a Buy rating on the shares following the company's Q2 results. With Adcetris' "strong" launch in frontline classical Hodgkin's lymphoma and record high quarter-to-quarter sales growth in hand, Seattle Genetics is ready to deliver "yet another near-term catalyst" in early Q4 with the topline results of the ECHELON-2 trial, Fein tells investors in a research note. He believes Adcetris plus cyclophosphamide, doxorubicin, and prednisone could offer significant improvement over current combination chemotherapy regimen in treating frontline mature T-cell lymphoma patients.
07/30/18
NEED
07/30/18
NO CHANGE
Target $79
NEED
Buy
Seattle Genetics price target raised to $79 from $74 at Needham
Needham analyst Chad Messer raised his price target on Seattle Genetics to $79 after its Q2 results, saying the sale of ADCETRIS were much higher than expected on its rapid rate of uptake in frontline Hodgins Lymphoma. Messer adds that further label expansion could come from ESCHELON-2 data expected to be out in Q4, while the company is also progressing with late stage programs such as Enfortumab Vedotoin for urothelial cancer, Tucatinib in metastatic breast cancer, and Tisotumab Vedotin in a pivotal cervical cancer study. Messer keeps his Buy rating on Seattle Genetics.
SHPG Shire
$177.31

4.93 (2.86%)

05/09/18
LEER
05/09/18
NO CHANGE
LEER
Takeda/Shire transaction shows path for consolidation, says Leerink
Leerink analyst Geoffrey Porges notes that Takeda (TKPYY) confirmed its intention and agreement to purchase Shire (SHPG) for $62B in cash and stock. For the broader biopharma industry, the analyst believes Takeda's ability to lever up to an estimated 5.4x net debt/EBITDA suggests that investors are underestimating the ability of large cap biopharma companies to pursue large transactions. Nearly all of the large cap biopharma companies face looming growth issues or suffer under revenue-concentration risk discounts that could be mitigated by large-scale acquisitions, he contends. Porges believes that if Takeda can execute the Shire acquisition while checking the boxes of investor demands of a net positive ROIC, instant EPS accretion, maintaining an investment grade credit rating, and massive synergy savings, then others in the biopharma industry with stronger balance sheets and larger valuations can contemplate transactions that are substantially larger even than Shire.
09/04/18
09/04/18
DOWNGRADE

Market Perform
Shire downgraded to Market Perform as spread narrows at Bernstein
As previously reported, Bernstein analyst Aaron Gal downgraded Shire (SHPG) to Market Perform from Outperform. The analyst notes that he current controversy on Shire is the risk/reward into the closing of the Takeda (TKPYY) acquisition, and over the past few weeks deal spread narrowed, and the fundamentals have gotten a bit tougher in ADHD, HAE and Hemophilia.
09/04/18
BERN
09/04/18
DOWNGRADE
BERN
Market Perform
Shire downgraded to Market Perform from Outperform at Bernstein
09/07/18
BREN
09/07/18
DOWNGRADE
BREN
Hold
Shire downgraded to Hold from Buy at Berenberg
Berenberg analyst Klara Fernandes downgraded Shire (SHPG) to Hold saying the current valuation offers limited potential upside ahead of the pending takeover by Takeda Pharmaceutical (TKPYY).
SNSS Sunesis
$1.86

-0.08 (-4.12%)

12/11/17
WELS
12/11/17
UPGRADE
Target $8
WELS
Outperform
Sunesis upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Jim Birchenough upgraded Sunesis Pharmaceuticals to Outperform following a review of updated data for novel BTK inhibitor vecabrutinib at the American Society of Hematology meeting. Expert feedback at the meeting suggests vecabrutinib could become treatment of choice for Imbruvica resistance and ultimately a preferred choice over Imbruvica as a frontline treatment in a $3B-plus BTK inhibitor market, Birchenough tells investors in a research note. The analyst expects positive vecabrutinib data despite recent management departures and upped his price target for Sunesis shares to $8 from $2.
12/05/17
WELS
12/05/17
DOWNGRADE
Target $2
WELS
Market Perform
Sunesis downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough downgraded Sunesis Pharmaceuticals to Market Perform following the resignation of the company's CEO Daniel Swisher. While the executive is pursuing an attractive opportunity at a larger biopharmaceutical company, the move highlights the early stage nature of Sunesis' pipeline, extended timelines for development and potential risk in realizing the potential for lead BTK inhibitor SNS062, Birchenough tells investors in a research note. The analyst cut his price target for the shares to $2 from $5.
12/05/17
CANT
12/05/17
NO CHANGE
Target $3
CANT
Neutral
Sunesis clinical picture unchanged with CEO leaving, says Cantor Fitzgerald
Cantor Fitzgerald analyst Mara Goldstein believes shares of Sunesis Pharmaceuticals could face pressure on the resignation of President and CEO Dan Swisher. The loss, however, is not an indictment of the clinical potential of SNS-062, Goldstein tells investors in a research note. However, the analyst believes the resignation makes it harder for investors to maintain focus on the company without a CEO at the helm, particularly as interim data are not expected until mid-2018. She keeps a Neutral rating on Sunesis with a $3 price target.
11/21/17
11/21/17
INITIATION
Target $7

Outperform
Oppenheimer says Sunesis has defined opportunity, initiates with Outperform
As previously reported, Oppenheimer analyst Hartaj Singh started Sunesis (SNSS) with an Outperform rating and $7 price target. While AbbVie's (ABBV) ibrutinib has demonstrated a robust risk/benefit profile across many tumor types, it is becoming apparent that about 10% or more of leukemia and lymphoma patients have a mutation that leads to relapse on ibrutinib, he contends. The analyst believes Sunesis' reversible and potent BTK inhibitor SNS-062 has the ability to address this patient population, both upon relapse following ibrutinib or directly through a biomarker-driven approach.
TEVA Teva
$22.84

0.63 (2.84%)

09/13/18
JEFF
09/13/18
NO CHANGE
Target $27
JEFF
Buy
Bausch bankruptcy risk arguably off table with settlement, says Jefferies
Bausch Health (BHC) yesterday announced an important settlement for Xifaxan with first to file Teva (TEVA), allowing for generic entry in January of 2028, Jefferies analyst David Steinberg tells investors in a research note. One could argue the settlement takes Bausch's bankruptcy risk off the table given the "long runway and greater certainty to future cash flows" from what is the company's most important drug, the analyst contends. Further, the deal could also allow the company to refinance its debt at more attractive terms. Steinberg keeps a Buy rating on Bausch Health with a $27 price target.
09/12/18
BMOC
09/12/18
NO CHANGE
Target $24
BMOC
Market Perform
Bausch Health settlement for Xifaxan shores up key franchise, says BMO Capital
After Bausch Health (BHC) announced a generic Xifaxan settlement with Teva's (TEVA) Actavis unit, BMO Capital analyst Gary Nachman called it "a very positive outcome" that shores up the durability of one of the company's key growth franchises. The analyst, who said Bausch's significant debt load likely remains a cap on the stock, keeps a Market Perform rating on the shares but raised his price target to $24 from $22.
09/13/18
PIPR
09/13/18
UPGRADE
Target $19
PIPR
Neutral
Bausch Health upgraded to Neutral from Underweight at Piper Jaffray
Piper Jaffray analyst David Amsellem upgraded Bausch Health to Neutral and raised his price target for the shares to $19 from $16. In a research note partially titled "Time To Lay Down Our Weapons," the analyst says he can longer argue company formerly known as Valeant Pharmaceuticals is not investable. Yesterday's settlement with Teva (TEVA) brings greater visibility into the durability of Xifaxan, Amsellem tells investors. While he does not view the stock as attractively valued, the analyst concedes that Bausch Health's annual EBITDA will trough at levels not much lower than its current 2018 guidance range of $3.20B-$3.35B.
09/13/18
HCWC
09/13/18
NO CHANGE
Target $25
HCWC
Neutral
Bausch Health price target raised to $25 from $20 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Bausch Health (BHC) to $25 after the company reached an agreement to resolve the outstanding intellectual property litigation regarding Xifaxan with Teva's (TEVA) Actavis Laboratories. While the analyst is "enthused" by the agreement, particularly since Actavis was the only entity to have received tentative approval of a generic rifaximin product, he notes that the competitive risks to Xifaxan "are not all in the rear view mirror quite yet." Other factors still remain to be clarified, including the status of the new drug application for Cosmo Pharmaceuticals' Rifamycin, which has an approval decision date of November 16, the analyst adds. Selvaraju keeps a Neutral rating on Bausch Health.

TODAY'S FREE FLY STORIES

AZN

AstraZeneca

$37.69

-0.025 (-0.07%)

12:59
09/23/18
09/23
12:59
09/23/18
12:59
Periodicals
AstraZeneca CEO warns of medicine shortages following Brexit, Reuters reports »

Britain could see…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$0.00

(0.00%)

12:54
09/23/18
09/23
12:54
09/23/18
12:54
Periodicals
Volkswagen's Porsche dropping diesel in EV push, Reuters says »

Volkswagen's Porsche…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$217.65

-2.35 (-1.07%)

12:49
09/23/18
09/23
12:49
09/23/18
12:49
Periodicals
Apple planning for delays to Battersea HQ, Bloomberg reports »

Apple is making…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

PYPL

PayPal

$90.76

0.17 (0.19%)

12:43
09/23/18
09/23
12:43
09/23/18
12:43
Periodicals
PayPal replaces executive in charge of Venmo, WSJ reports »

PayPal is replacing the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

MDT

Medtronic

$97.85

0.38 (0.39%)

12:37
09/23/18
09/23
12:37
09/23/18
12:37
Hot Stocks
Medtronic presents IN.PACT global study three-year data »

Medtronic announced data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

CMCSA

Comcast

$37.91

0.1 (0.26%)

, CMCSK

Comcast

$0.00

(0.00%)

12:29
09/23/18
09/23
12:29
09/23/18
12:29
Hot Stocks
Comcast prevails with highest offer price in auction for Sky »

Comcast (CMCSA) published…

CMCSA

Comcast

$37.91

0.1 (0.26%)

CMCSK

Comcast

$0.00

(0.00%)

SKYAY

Sky

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$97.85

0.38 (0.39%)

12:26
09/23/18
09/23
12:26
09/23/18
12:26
Hot Stocks
Clinical study shows safety, efficacy outcomes for Medtronic Resolute Onyx DES »

Investigators unveiled…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

BSX

Boston Scientific

$37.76

-0.07 (-0.19%)

12:20
09/23/18
09/23
12:20
09/23/18
12:20
Hot Stocks
Boston Scientific announced positive 12-month data from IMPERIAL trial »

Boston Scientific…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

NITE

Nightstar Therapeutics

$25.64

-1.71 (-6.25%)

12:16
09/23/18
09/23
12:16
09/23/18
12:16
Hot Stocks
Nightstar reports proof of concept data from dose escalation in XIRIUS trial »

Nightstar Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

AERI

Aerie Pharmaceuticals

$58.50

0.1 (0.17%)

, AGN

Allergan

$191.34

-1.11 (-0.58%)

04:55
09/23/18
09/23
04:55
09/23/18
04:55
Conference/Events
European Society of Retina Specialists to hold a conference »

18th Congress of EURETINA…

AERI

Aerie Pharmaceuticals

$58.50

0.1 (0.17%)

AGN

Allergan

$191.34

-1.11 (-0.58%)

ALIM

Alimera Sciences

$1.07

(0.00%)

BABY

Natus Medical

$34.45

-0.2 (-0.58%)

BHC

Bausch Health

$24.92

-0.07 (-0.28%)

BAYRY

Bayer

$0.00

(0.00%)

ELXMF

Ellex Medical Lasers

$0.00

(0.00%)

GKOS

Glaukos

$58.78

-1.69 (-2.79%)

IRIX

IRIDEX

$6.52

0.08 (1.24%)

JNJ

Johnson & Johnson

$142.85

0.85 (0.60%)

NITE

Nightstar Therapeutics

$25.64

-1.71 (-6.25%)

NVS

Novartis

$85.46

-0.505 (-0.59%)

OCUL

Ocular Therapeutix

$6.45

0.03 (0.47%)

RHHBY

Roche

$0.00

(0.00%)

SHPG

Shire

$178.32

-1.68 (-0.93%)

STAA

STAAR Surgical

$47.00

-0.9 (-1.88%)

TMDI

Titan Medical

$2.24

0.02 (0.90%)

TTNP

Titan Pharmaceuticals

$0.22

-0.2833 (-56.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 25

    Sep

  • 27

    Sep

  • 01

    Oct

  • 03

    Oct

  • 09

    Oct

  • 16

    Oct

  • 22

    Oct

  • 28

    Oct

  • 29

    Oct

  • 15

    Nov

  • 27

    Nov

  • 21

    Dec

  • 28

    Dec

  • 15

    Feb

  • 25

    Feb

CMCSA

Comcast

$37.91

0.1 (0.26%)

, CMCSK

Comcast

$0.00

(0.00%)

14:32
09/22/18
09/22
14:32
09/22/18
14:32
Periodicals
Comcast outbids Fox in battle for Sky, Reuters reports »

Comcast (CMCSA; CMCSK)…

CMCSA

Comcast

$37.91

0.1 (0.26%)

CMCSK

Comcast

$0.00

(0.00%)

FOX

21st Century Fox

$43.97

-0.23 (-0.52%)

FOXA

21st Century Fox

$44.33

-0.26 (-0.58%)

SKYAY

Sky

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOKF

BOK Financial

$104.69

-0.08 (-0.08%)

, COBZ

CoBiz Financial

$23.44

0.01 (0.04%)

13:36
09/22/18
09/22
13:36
09/22/18
13:36
Conference/Events
CoBiz Financial to host special shareholder meeting »

Special Shareholder…

BOKF

BOK Financial

$104.69

-0.08 (-0.08%)

COBZ

CoBiz Financial

$23.44

0.01 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Sep

AMRH

AMERI Holdings

$1.44

-0.04 (-2.70%)

13:30
09/22/18
09/22
13:30
09/22/18
13:30
Conference/Events
AMERI Holdings to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

BRK.A

Berkshire Hathaway

$331,710.00

-1090 (-0.33%)

13:26
09/22/18
09/22
13:26
09/22/18
13:26
Periodicals
Berkshire Hathaway still looks underpriced, Barron's says »

Class A shares of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLGO

BioLargo

$0.00

(0.00%)

13:11
09/22/18
09/22
13:11
09/22/18
13:11
Conference/Events
BioLargo to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZWI

Citizens Community Bancorp

$14.13

0.03 (0.21%)

12:56
09/22/18
09/22
12:56
09/22/18
12:56
Conference/Events
Citizens Community Bancorp to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SF

Stifel Financial

$54.86

-0.78 (-1.40%)

12:50
09/22/18
09/22
12:50
09/22/18
12:50
Conference/Events
Stifel Financial to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBCT

People's United

$17.94

-0.055 (-0.31%)

, FBNK

First Connecticut

$30.95

0.1 (0.32%)

12:47
09/22/18
09/22
12:47
09/22/18
12:47
Conference/Events
First Connecticut to host special shareholder meeting »

Special shareholder…

PBCT

People's United

$17.94

-0.055 (-0.31%)

FBNK

First Connecticut

$30.95

0.1 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 18

    Oct

ASPS

Altisource

$34.10

-0.09 (-0.26%)

12:44
09/22/18
09/22
12:44
09/22/18
12:44
Conference/Events
Altisource to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$217.65

-2.35 (-1.07%)

, CSCO

Cisco

$48.51

0.77 (1.61%)

12:36
09/22/18
09/22
12:36
09/22/18
12:36
Periodicals
Apple, Microsoft among stocks with solid dividends, Barron's says »

Technology stocks are not…

AAPL

Apple

$217.65

-2.35 (-1.07%)

CSCO

Cisco

$48.51

0.77 (1.61%)

IBM

IBM

$151.29

0.12 (0.08%)

MSFT

Microsoft

$114.70

1.13 (0.99%)

ORCL

Oracle

$51.08

0.65 (1.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

  • 03

    Oct

  • 04

    Oct

  • 05

    Oct

  • 10

    Oct

  • 21

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 25

    Oct

  • 28

    Oct

  • 28

    Nov

  • 03

    Mar

CAT

Caterpillar

$156.39

0.38 (0.24%)

, AMAT

Applied Materials

$39.62

0.22 (0.56%)

12:28
09/22/18
09/22
12:28
09/22/18
12:28
Periodicals
Caterpillar, KeyCorp among stocks to buy as bond yields rise, Barron's says »

As the economy improves,…

CAT

Caterpillar

$156.39

0.38 (0.24%)

AMAT

Applied Materials

$39.62

0.22 (0.56%)

BWA

BorgWarner

$45.24

-0.53 (-1.16%)

KEY

KeyCorp

$20.78

0.02 (0.10%)

PH

Parker-Hannifin

$190.52

0.01 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Sep

  • 18

    Oct

  • 25

    Oct

  • 30

    Oct

BSX

Boston Scientific

$37.76

-0.07 (-0.19%)

, ISRG

Intuitive Surgical

$556.70

-4.43 (-0.79%)

10:34
09/22/18
09/22
10:34
09/22/18
10:34
Periodicals
'Good time' to think about device markers, Barron's says »

Medical technology stocks…

BSX

Boston Scientific

$37.76

-0.07 (-0.19%)

ISRG

Intuitive Surgical

$556.70

-4.43 (-0.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

TLRY

Tilray

$123.16

-53.365 (-30.23%)

10:20
09/22/18
09/22
10:20
09/22/18
10:20
Periodicals
Marijuana stocks 'the new Bitcoin,' Barron's says »

Led by Tilray, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$217.65

-2.35 (-1.07%)

, WMT

Walmart

$95.85

0.1 (0.10%)

09:05
09/22/18
09/22
09:05
09/22/18
09:05
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$217.65

-2.35 (-1.07%)

WMT

Walmart

$95.85

0.1 (0.10%)

DE

Deere

$152.82

-1.24 (-0.80%)

AGCO

Agco

$60.24

-0.9 (-1.47%)

ADM

Archer Daniels

$50.33

(0.00%)

MOS

Mosaic

$32.33

0.02 (0.06%)

CF

CF Industries

$52.82

-0.48 (-0.90%)

SPWR

SunPower

$7.88

-0.18 (-2.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 28

    Oct

  • 06

    Nov

  • 13

    Nov

  • 15

    Nov

  • 03

    Mar

AERI

Aerie Pharmaceuticals

$58.50

0.1 (0.17%)

, AGN

Allergan

$191.34

-1.11 (-0.58%)

04:55
09/22/18
09/22
04:55
09/22/18
04:55
Conference/Events
European Society of Retina Specialists to hold a conference »

18th Congress of EURETINA…

AERI

Aerie Pharmaceuticals

$58.50

0.1 (0.17%)

AGN

Allergan

$191.34

-1.11 (-0.58%)

ALIM

Alimera Sciences

$1.07

(0.00%)

BABY

Natus Medical

$34.45

-0.2 (-0.58%)

BHC

Bausch Health

$24.92

-0.07 (-0.28%)

BAYRY

Bayer

$0.00

(0.00%)

ELXMF

Ellex Medical Lasers

$0.00

(0.00%)

GKOS

Glaukos

$58.78

-1.69 (-2.79%)

IRIX

IRIDEX

$6.52

0.08 (1.24%)

JNJ

Johnson & Johnson

$142.85

0.85 (0.60%)

NITE

Nightstar Therapeutics

$25.64

-1.71 (-6.25%)

NVS

Novartis

$85.46

-0.505 (-0.59%)

OCUL

Ocular Therapeutix

$6.45

0.03 (0.47%)

RHHBY

Roche

$0.00

(0.00%)

SHPG

Shire

$178.32

-1.68 (-0.93%)

STAA

STAAR Surgical

$47.00

-0.9 (-1.88%)

TMDI

Titan Medical

$2.24

0.02 (0.90%)

TTNP

Titan Pharmaceuticals

$0.22

-0.2833 (-56.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 24

    Sep

  • 25

    Sep

  • 27

    Sep

  • 01

    Oct

  • 03

    Oct

  • 09

    Oct

  • 16

    Oct

  • 22

    Oct

  • 28

    Oct

  • 29

    Oct

  • 15

    Nov

  • 27

    Nov

  • 21

    Dec

  • 28

    Dec

  • 15

    Feb

  • 25

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.